CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) (NCT06834282)
Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)
π©Ί Plain-English Summary (8th-Grade Level)
This is a ο¬rst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efο¬cacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Who can join: Review the eligibility criteria below.
Location: University of California, Davis Comprehensive Cancer Center β Sacramento, California
Age range: 18 Years to 85 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (5 Sites)
- University of California, Davis Comprehensive Cancer Center β Sacramento, California
- Colorado Blood Cancer Institute β Denver, Colorado
- Sarah Cannon Research Insitute β Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center β Houston, Texas
- Fred Hutchinson Cancer Center β Seattle, Washington
π Contact the Study Coordinator
Phone: (916) 382-6970
Email: bajonas@health.ucdavis.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in AML
- ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial β Houston, Texas
- A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant β Rochester, New York
- A Long Term Follow-up Study of TScan TCR-T Products β Duarte, California
- Cardioprotection in AML β Charlottesville, Virginia
- UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy β Birmingham, Alabama
Explore by condition: All AML clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.